Teva Pharma Industries (NYSE: TEVA) — Perfil da empresa, notícias e dados financeiros
Teva Pharma Industries develops generic and specialty medicines globally, enhancing access to affordable healthcare across various therapeutic areas.
Teva Pharma Industries
Teva Pharma Industries is a global biopharmaceutical company engaged in the development, manufacturing, and commercialization of generic medicines, biosimilars, over-the-counter health products, and specialty innovative pharmaceuticals. The company's product portfolio focuses on therapeutic areas including neuroscience, immunology, oncology, and respiratory care. Teva operates an integrated commercial and supply chain infrastructure spanning North America, Europe, and international growth markets, delivering medicines to healthcare systems and patients worldwide. Its business model combines a global scale generics and biosimilars operation with ongoing research and development into novel biopharmaceutical treatments and targeted therapeutic solutions.
Resumo
Operações
Produtos e/ou serviços de Teva Pharma Industries
- Generic Medicines: Manufacturing and global distribution of prescription generic pharmaceuticals across oral solid dosage forms, injectables, respiratory inhalers, and complex formulations, providing cost-effective treatments across primary therapeutic areas and regional healthcare markets.
- Innovative Neuroscience Medicines: Development and commercialization of specialized branded prescription pharmaceuticals for central nervous system disorders, focusing on movement disorders, severe psychiatric conditions, tardive dyskinesia, and targeted preventive treatments for chronic migraine.
- Biosimilar Products: Development, strategic partnering, and commercial distribution of follow-on biological therapies across oncology and immunology, offering high-quality biological treatment options that expand patient access to complex biopharmaceutical remedies worldwide.
- Immunology and Respiratory Therapies: Commercialization and advanced clinical pipeline development of targeted biopharmaceutical products for autoimmune diseases, inflammatory bowel conditions, asthma, and chronic obstructive pulmonary disease across major international markets.
- Over-the-Counter Consumer Healthcare: Formulation, production, and distribution of non-prescription consumer healthcare products, self-care remedies, and dietary supplements sold through retail pharmacies and commercial distribution networks across Europe and international markets.
- Active Pharmaceutical Ingredients: Development, chemical synthesis, and commercial supply of bulk active pharmaceutical ingredients and active intermediates to internal drug production operations as well as external third-party pharmaceutical manufacturers worldwide.
equipe executiva do Teva Pharma Industries
- Richard D. FrancisPresident, CEO & Director
- Eliyahu Sharon KalifExecutive VP & CFO
- Eric A. HughesExecutive VP of Global R&D and Chief Medical Officer
- Christine FoxExecutive VP of US Commercial & Head of Innovative Franchise
- Evan LippmanExecutive Vice President of Business Development
- Matthew ShieldsExecutive Vice President of Global Operations
- Amir WeissSenior VP & Chief Accounting Officer
- Christopher J. StevoSenior Vice President of Investor Relations & Competitive Intelligence
- Kathleen VeitSenior Vice President, Global Compliance & Ethics Officer
- Brian SavageInterim Chief Legal Officer
Últimas notícias sobre a Teva Pharma Industries
Teva wins FDA approval for WELTRUZA
United StatesTeva reports positive celiac drug trial results
United StatesTeva receives FDA priority review for Tourette drug
United StatesTeva signs global multiple sclerosis biosimilar agreement
United StatesTeva launches AHZANTIVE, an Aflibercept biosimilar, across key European markets
United StatesEuropean regulators accept Teva and Medincell’s application for long-acting Schizophrenia injection
United States
Histórico de dividendos
Dividendos por ação pagos pela Teva Pharma Industries , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2017 | — | — | — | $0.8500 |
| FY2016 | — | — | — | $1.3600 |
| FY2015 | — | — | — | $1.3600 |
| FY2014 | — | — | — | $1.3660 |
| FY2013 | — | — | — | $1.2780 |
Principais indicadores financeiros
Resultados divulgados pela Teva Pharma Industries , em USD.
- Cap. de mercado
- 47,1 bi
- Receita (TTM)
- 17,3 bi
- P/L
- 67.3
- LPA (diluído, TTM)
- 0.6
- Dividend yield
- —
- Margem de lucro
- 4.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 17,3 bi | 2,2 bi | 1,4 bi | |
| 16,5 bi | -303 mi | -1,6 bi | |
| 15,8 bi | 433 mi | -559 mi | |
| 14,9 bi | -2,2 bi | -2,4 bi |